FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202326704> ?p ?o ?g. }

• W3202326704 endingPage "1468" @default.
• W3202326704 startingPage "1457" @default.
• W3202326704 abstract "BACKGROUND: Few studies have examined oral anticancer treatment utilization patterns among Medicare beneficiaries. OBJECTIVE: To assess treatment utilization patterns of newly initiated oral anticancer agents across national samples of Medicare beneficiaries for 5 cancer types: chronic myeloid leukemia (CML), multiple myeloma (MM), metastatic prostate cancer (mPC), metastatic renal cell carcinoma (mRCC), and metastatic breast cancer (mBC). METHODS: This retrospective claims analysis used 100% Medicare Chronic Condition Data Warehouse (CCW) Parts A, B, and D files from 2011 to 2014 (for CML, MM, mPC, and mRCC patients) and a 5% random fee-for-service sample from 2011 to 2013 (for mBC patients). Outcomes of interest were the number of 30-day supply prescriptions, adherence, and discontinuation of newly initiated (ie, index) oral anticancer agents indicated for each of the cancers. Adherence was calculated with both the “traditional” proportion of days covered (PDC) approach, measured over a fixed 1-year period or until hospice/death, and a “modified” PDC approach, measured over the time between the first and last fill of the index oral anticancer agent. Patients with PDC of at least 0.80 were deemed as being adherent. Discontinuation was defined as the presence of a continuous 90-day gap in the availability of days supply of the index oral anticancer agent. RESULTS: Our study included 1,650, 7,461, 6,998, 2,553, and 79 patients for CML, MM, mPC, mRCC, and mBC, respectively. Patients with mRCC had the highest proportion of patients with only 1 fill of their index anticancer agent (28%) followed by mBC (17%), MM (17%), mPC (12%), and CML (12%). Patients with CML had the highest mean (SD) number of 30-day supply equivalent prescriptions (8.3 [4.6]), followed by patients with mPC (6.5 [4.2]), MM (5.7 [4.1]), mBC (4.7 [3.2]), and mRCC (4.5 [3.9]). Using the modified PDC measured between the first and last fills, approximately three-quarters of patients with CML (74%), mRCC (71%), and mBC (70%) were adherent to the index oral anticancer agent. Adherence was highest for patients with mPC (87%) and lowest for patients with MM (58%). The percentage of patients defined as adherent to the index oral anticancer agent decreased for all cancers when using the traditional PDC measure over a fixed 1-year period: CML (54%), MM (35%), mPC (48%), mRCC (37%), and mBC (22%). Rates of discontinuation for patients in our sample were 32% (CML), 38% (mPC), 42% (mRCC), 48% (MM), and 58% (mBC). CONCLUSIONS: Between 13% and 42% of Medicare patients were nonadherent between the first and last fill of their newly initiated oral anticancer therapies across a range of cancers. This study provides a valuable benchmark for stakeholders seeking to measure and improve adherence to oral anticancer agents in Medicare patients. DISCLOSURES: This study was supported by Humana, Inc. (Louisville, KY). The sponsor played a role in the development of the study protocol, interpretation of results, and revisions of the manuscript. The sponsor was not involved in data analysis. Brown is employed by Humana, Inc., and Ward was employed by Humana, Inc., from research inception through initial drafts. Doshi has served as an advisory board member or consultant for Allergan, Ironwood Pharmaceuticals, Janssen, Kite Pharma, Merck, Otsuka, Regeneron, Sarepta, Sage Therapeutics, Sanofi, and Vertex and has received research funding from AbbVie, Biogen, Humana, Janssen, Novartis, PhRMA, Regeneron, Sanofi, and Valeant. Her spouse holds stock in Merck and Pfizer. All other authors have no financial conflicts of interest to report." @default.
• W3202326704 created "2021-10-11" @default.
• W3202326704 creator A5010673372 @default.
• W3202326704 creator A5012747659 @default.
• W3202326704 creator A5020002044 @default.
• W3202326704 creator A5024235134 @default.
• W3202326704 creator A5041730686 @default.
• W3202326704 creator A5045235614 @default.
• W3202326704 creator A5065207720 @default.
• W3202326704 creator A5087878848 @default.
• W3202326704 date "2021-10-01" @default.
• W3202326704 modified "2023-10-02" @default.
• W3202326704 title "Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries" @default.
• W3202326704 cites W122612806 @default.
• W3202326704 cites W1991181074 @default.
• W3202326704 cites W2029424278 @default.
• W3202326704 cites W2036751910 @default.
• W3202326704 cites W2044272856 @default.
• W3202326704 cites W2074048861 @default.
• W3202326704 cites W2096277311 @default.
• W3202326704 cites W2106277150 @default.
• W3202326704 cites W2111237172 @default.
• W3202326704 cites W2134744700 @default.
• W3202326704 cites W2140974115 @default.
• W3202326704 cites W2142413768 @default.
• W3202326704 cites W2162796269 @default.
• W3202326704 cites W2167325977 @default.
• W3202326704 cites W2273757369 @default.
• W3202326704 cites W2284819073 @default.
• W3202326704 cites W2501830993 @default.
• W3202326704 cites W2518111948 @default.
• W3202326704 cites W2529061634 @default.
• W3202326704 cites W2614466076 @default.
• W3202326704 cites W2622040865 @default.
• W3202326704 cites W2744308326 @default.
• W3202326704 cites W2749674352 @default.
• W3202326704 cites W2764030073 @default.
• W3202326704 cites W2789916977 @default.
• W3202326704 cites W2802007547 @default.
• W3202326704 cites W2804377180 @default.
• W3202326704 cites W2922271103 @default.
• W3202326704 doi "https://doi.org/10.18553/jmcp.2021.27.10.1457" @default.
• W3202326704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34595957" @default.
• W3202326704 hasPublicationYear "2021" @default.
• W3202326704 type Work @default.
• W3202326704 sameAs 3202326704 @default.
• W3202326704 citedByCount "4" @default.
• W3202326704 countsByYear W32023267042022 @default.
• W3202326704 countsByYear W32023267042023 @default.
• W3202326704 crossrefType "journal-article" @default.
• W3202326704 hasAuthorship W3202326704A5010673372 @default.
• W3202326704 hasAuthorship W3202326704A5012747659 @default.
• W3202326704 hasAuthorship W3202326704A5020002044 @default.
• W3202326704 hasAuthorship W3202326704A5024235134 @default.
• W3202326704 hasAuthorship W3202326704A5041730686 @default.
• W3202326704 hasAuthorship W3202326704A5045235614 @default.
• W3202326704 hasAuthorship W3202326704A5065207720 @default.
• W3202326704 hasAuthorship W3202326704A5087878848 @default.
• W3202326704 hasBestOaLocation W32023267041 @default.
• W3202326704 hasConcept C121608353 @default.
• W3202326704 hasConcept C126322002 @default.
• W3202326704 hasConcept C143998085 @default.
• W3202326704 hasConcept C167135981 @default.
• W3202326704 hasConcept C2426938 @default.
• W3202326704 hasConcept C2777472916 @default.
• W3202326704 hasConcept C2778715236 @default.
• W3202326704 hasConcept C71924100 @default.
• W3202326704 hasConcept C98274493 @default.
• W3202326704 hasConceptScore W3202326704C121608353 @default.
• W3202326704 hasConceptScore W3202326704C126322002 @default.
• W3202326704 hasConceptScore W3202326704C143998085 @default.
• W3202326704 hasConceptScore W3202326704C167135981 @default.
• W3202326704 hasConceptScore W3202326704C2426938 @default.
• W3202326704 hasConceptScore W3202326704C2777472916 @default.
• W3202326704 hasConceptScore W3202326704C2778715236 @default.
• W3202326704 hasConceptScore W3202326704C71924100 @default.
• W3202326704 hasConceptScore W3202326704C98274493 @default.
• W3202326704 hasIssue "10" @default.
• W3202326704 hasLocation W32023267041 @default.
• W3202326704 hasLocation W32023267042 @default.
• W3202326704 hasLocation W32023267043 @default.
• W3202326704 hasOpenAccess W3202326704 @default.
• W3202326704 hasPrimaryLocation W32023267041 @default.
• W3202326704 hasRelatedWork W2005149537 @default.
• W3202326704 hasRelatedWork W2034700291 @default.
• W3202326704 hasRelatedWork W2065430497 @default.
• W3202326704 hasRelatedWork W2154386650 @default.
• W3202326704 hasRelatedWork W2172111759 @default.
• W3202326704 hasRelatedWork W2466043692 @default.
• W3202326704 hasRelatedWork W2735157618 @default.
• W3202326704 hasRelatedWork W2901824973 @default.
• W3202326704 hasRelatedWork W4306252664 @default.
• W3202326704 hasRelatedWork W4308256219 @default.
• W3202326704 hasVolume "27" @default.
• W3202326704 isParatext "false" @default.
• W3202326704 isRetracted "false" @default.
• W3202326704 magId "3202326704" @default.
• W3202326704 workType "article" @default.